title: Paraventricular nucleus administration of DuP753 or PD123319 inhibits the effects of angiotensin on water and sodium intake.
abstract: We determined the effects of DuP753 and PD123319 (both nonpeptides and selective antagonists of the AT1 and AT2 angiotensin receptors, respectively), and [Sar1, Ala8]ANG II(a non-selective peptide antagonist of angiotensin receptors) on water and 3% NaCl intake induced by administration of angiotensin II (ANG II) into the paraventricular nucleus (PVN) of sodium-depleted Holtzman rats weighing 250-300 g. Twenty hours before the experiments, the rats were depleted of sodium using furosemide (10 ng/rat, sc). The volume of drug solution injected was 0.5 microliters over a period of 10-15 sec. Water and sodium intake were measured at 0.25, 0.5, 1.0 and 2.0 h. Pre-treatment with DuP753 (14 rats) at a dose of 60 ng completely abolished the water intake induced by injection of 12 ng of ANG II (15 rats) (6.4 +/- 0.6 vs 1.4 +/- 0.3 ml/2 h), whereas [Sar1, Ala8] ANG II (12 rats) and PD123319 (10 rats) at the doses of 60 ng partially blocked water intake (6.4 +/- 0.6 vs 2.9 +/- 0.5 and 2.7 +/- 0.2 ml/h, respectively). In the same animals, [Sar1, Ala8]ANG II, DuP753, and PD123319 blocked the sodium intake induced by ANG II (9.2 +/- 1.6 vs 3.3 +/- 0.6, 1.8 +/- 0.3, and 1.4 +/- 0.2 ml/2 h respectively). These results indicate that both DuP753 and PD123329, administered into the PVN, blocked the water and sodium intake induced by administration of ANG II into the same site.
authors.affiliation: Departamento de Ciências Fisiológicas, Faculdade de Odontologia, Universidade Estadual Paulista, Araraquara, SP, Brasil.
authors.forename: M H
authors.initials: MH
authors.lastname: do-Prado
authors.forename: G M
authors.initials: GM
authors.lastname: Camargo
authors.forename: A
authors.initials: A
authors.lastname: Renzi
authors.forename: W A
authors.initials: WA
authors.lastname: Saad
authors.forename: A C
authors.initials: AC
authors.lastname: Luiz
authors.forename: R C
authors.initials: RC
authors.lastname: Queiróz
authors.forename: L A
authors.initials: LA
authors.lastname: Camargo
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D004326:Drinking / Q000187:drug effects*; D007093:Imidazoles / Q000008:administration & dosage* / Q000494:pharmacology; D019808:Losartan; D008297:Male; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects*; D011725:Pyridines / Q000008:administration & dosage* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012982:Sodium, Dietary / Q000008:administration & dosage*; D013777:Tetrazoles / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D007093:Imidazoles; D011725:Pyridines; D012982:Sodium, Dietary; D013777:Tetrazoles; D000804:Angiotensin II; C073402:PD 123319; D019808:Losartan